anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an immunological carcinostatic agent having broad carcinostatic spectrum, by preparing a water-soluble or easily water-dispersible protein and glycoprotein from the raw cell membrane of the organs of mammals through specific steps, and using the protein, etc. as active components. CONSTITUTION:The organs of mammals, preferably the livers, spleens, etc. of cattle, pig, etc. are cleaned by removing the blood vessel, connective tissue, and adipose tissue therefrom, and the remaining cells are homogenized together with an isotonic liquid. The homogenized liquid is centrifuged, and the obtained supernatant liquid is dialyzed with an isotonic liquid or water. The dialyzed liquid is concentrated and dried to obtain water-soluble or easily water-dispersible protein and glycoprotein, which are used as the objective immunological carcinostatic agent. The immunological carcinostatic activity can be further improved and the preservability can be improved, by adding an aldehyde compound as a biotissue fixing agent to the supernatant liquid obtained by the centrifugal separation, thereby immobilizing the active component.
Olanzapine, an atypical antipsychotic medication, has gained prominence in the treatment of schizophrenia and related psychotic disorders due to its effectiveness and perceived safety profile. However, emerging evidence suggests a potential link between olanzapine use and adverse cardiovascular effects, including cardiomyopathy. This narrative review explores the mechanisms, clinical implications, and management strategies associated with olanzapine-induced cardiomyopathy. A comprehensive review of the literature was conducted to investigate the relationship between olanzapine and cardiomyopathy. The search included epidemiological studies, clinical case reports, and mechanistic research focusing on the pathophysiology of olanzapine-induced cardiomyopathy. The review also examined treatment strategies for managing this potential complication. Olanzapine-induced cardiomyopathy is hypothesized to be associated with metabolic disturbances and receptor antagonism. The metabolic effects of olanzapine, such as weight gain, insulin resistance, and dyslipidemia, share similarities with obesity-related cardiomyopathy. Additionally, olanzapine's antagonism of certain receptors may contribute to cardiovascular stress. The review highlighted that patients with new-onset heart failure and significant weight gain while on olanzapine should be closely monitored for signs of cardiomyopathy. Early detection and prompt withdrawal of olanzapine, along with initiation of goal-directed medical therapy, are crucial for mitigating this potentially life-threatening condition. The relationship between olanzapine and cardiomyopathy is complex and not yet fully understood. However, the potential for significant cardiovascular risk necessitates vigilance among healthcare providers. Early identification and management of olanzapine-induced cardiomyopathy can improve patient outcomes. Further research is needed to elucidate the precise mechanisms behind this adverse effect and to develop optimized treatment strategies for patients requiring antipsychotic therapy.
PURPOSE:To obtain a remedy for keloid, effective in decreasing the height of keloid, exhibiting excellent effect for lessening the stretching feeling, having high safety and useful for the amelioration of various symptoms of keloid by using ethanolamine or its salt as an active component. CONSTITUTION:Ethanolamine or its salt (hydrochloride, sulfate, nitrate, acetate, citrate, fumarate, etc.) is used as an active component. The remedy is effective against various keloids such as true keloid, cicatricial keloid and false keloid. The remedy is applied usually by transcutaneous absorption in the form of ointment, gel, cream, liquid, spray, plaster, lotion, etc. The amount of ethanolamine or its salt is usually 0.01-20wt.%, preferably 0.05-5wt.% in terms of ethanolamine.
Both cyclosporine doses and the target range for whole blood trough concentrations should be reduced, when given in a regimen with everolimus, in order to minimize the risk of nephrotoxicity [see Warnings and Precautions (5.6), Drug Interactions (7.2), Clinical Pharmacology (12.8)].

The recommended cyclosporine therapeutic ranges when administered with everolimus are 100 to 200 ng/mL through Month 1 post transplant, 75 to 150 ng/mL at Months 2 and 3 post transplant, 50 to 100 ng/mL at Month 4 post transplant, and 25 to 50 ng/mL from Month 6 through Month 12 post transplant. The median trough concentrations observed in the clinical trial ranged between 161 to 185 ng/mL through Month 1 post transplant and between 111 to 140 ng/mL at Months 2 and 3 post transplant. The median trough concentration was 99 ng/mL at Month 4 post transplant and ranged between 46 to 75 ng/mL from Months 6 through Month 12 post transplant [see Clinical Pharmacology (12.8), Clinical Studies (14.1)].

Cyclosporine, USP Modified is to be administered as oral capsules twice daily unless cyclosporine oral solution or intravenous administration of cyclosporine cannot be avoided. Cyclosporine, USP Modified should be initiated as soon as possible - and no later than 48 hours - after reperfusion of the graft and dose adjusted to target concentrations from Day 5 onwards.

If impairment of renal function is progressive the treatment regimen should be adjusted. In renal transplant patients, the cyclosporine dose should be based on cyclosporine whole blood trough concentrations [see Clinical Pharmacology (12.8)].

In renal transplantation, there are limited data regarding dosing everolimus with reduced cyclosporine trough concentrations of 25 to 50 ng/mL after 12 months. Everolimus has not been evaluated in clinical trials with other formulations of cyclosporine. Prior to dose reduction of cyclosporine, it should be ascertained that steady-state everolimus whole blood trough concentration is at least 3 ng/mL. There is an interaction of cyclosporine on everolimus, and consequently, everolimus concentrations may decrease if cyclosporine exposure is reduced [see Drug Interactions (7.2)].
<P>PROBLEM TO BE SOLVED: To provide royal jelly-containing gene expression inhibitors and gene expression promoters; and to provide a method of detecting them.  <P>SOLUTION: Gene expression inhibitors containing royal jelly or its fraction have an effect of inhibiting expression of genes containing at least one base sequence selected from SEQ ID Nos. 1 to 5, and gene expression promoters containing royal jelly or its fraction have an effect of promoting expression of genes containing at least one base sequence selected from SEQ ID Nos. 6 to 13. The gene expression inhibitors or the gene expression promoters have anti-inflammatory effects, keratinization abnormality accumulation inhibiting effects, wound-healing promoting effects and/or moistening effects.  <P>COPYRIGHT: (C)2010,JPO&INPIT
FIELD: medicine. ^ SUBSTANCE: invention is referred to the area of medicine, namely rheumatology, immunology and biotechnology and is related to lowering of content of DNA-containing circulating immune complexes in blood. In order to do that the blood is filtered through the original combined sorbent which is a composition consisting of granulated drug with immobilized DNAse I and granulated drug with immobilized Clq-component of complement. Both drugs are being synthesized separately using the emulsion polymerization method in the gaseous nitrogen flow on the basis of polyacrylamide carrier with magnetic properties which is granulated at the 2:1 carrier: iron ratio. ^ EFFECT: method provides for significant decrease of release of duplex DNA antibodies that are released into the blood flow in process of destruction of DNA-containing circulating immune complexes, while maintaining the effectiveness of destruction of said complexes. ^ 1 dwg, 2 ex, 2 tbl
PURPOSE: This study aimed to examine the effect of birth ball exercise on labor pain, delivery duration, birth comfort, and birth satisfaction.
METHODS: The study used a randomized controlled trial design. All 120 primiparous pregnant women were randomly assigned to the intervention (IG) and control groups (CG). After the cervical dilatation reached 4 cm, the pregnant women in the IG performed birth ball exercises, adhering to the birth ball guide created by the researcher. No intervention was made in the control group other than standard midwifery care practices.
RESULTS: The labor pain level between the groups (VAS 1-when cervical dilatation was 4 cm) was similar to each other. The labor pain level (VAS 2- when cervical dilatation was 9 cm) scores of the women in the IG were significantly lower than those in the CG (p < 0.05). The time between the active phase of labor until dilatation is complete and the time until the baby's head comes out after full dilatation was found to be statistically significantly shorter in the IG compared to the CG (p < 0.05). Childbirth comfort and satisfaction mean scores between the groups were found to be statistically insignificant (p >  0.05).
CONCLUSION: As a result of the study, it was determined that the birth ball exercise significantly reduced labor pain and labor time. We recommend that the birth ball exercise be applied to all low-risk pregnant women because it helps fetal descent and cervical dilatation, and shortens labor pain and delivery time.
PURPOSE:A nonaqueous makeup cosmetic, obtained by incorporating a specific silicone oil having a high viscosity with a solid oil, volatile oil and pigment, having improved water and oil resistance and further improved stability with time and usability. CONSTITUTION:A nonaqueous makeup cosmetic obtained by incorporating (A) a solid oil such as solid wax, e.g. Japan wax, solid hydrocarbon, e.g. solid paraffin wax, solid higher fatty acid, e.g. stearic acid, (B) a volatile oil such as a low- boiling isoparaffin based hydrocarbon or low-boiling silicone oil, (C) a pigment usually used in a cosmetic and (D) a silicone oil having a viscosity as high as 100000-1000000cSt, particularly 300000-1000000cSt range, preferably dimethylpolysiloxane, as essential components. The preferred amounts of the respective components to be incorporated based on the total weight of the cosmetic are as follows; Within 5-20wt% range component (A), 30-60wt% range component (B), 15-30wt% range component (C) and 10-40wt% range component (D).
Mixtures of essentially satd. hydrocarbons which are in gel-form at room temp. can be used in the prophylaxis of inhalation allergies esp. of atopic rhinitis of the hay fever type. The gel is used in the form of a nasal ointment which is free from other components and which is applied to the upper portion of the vestibulum nasi, esp. in the region of each linear nasi. USE/ADVANTAGE - The gel can be used in the prophylaxis of allergies of the hay fever type caused by e.g. pollen, fungal spores, sawdust, flour, feathers, animal hairs etc.. The metabolism of the sufferer is unaffected by systemic substances and the largely inert hydrocarbons are not resorbed.  Thus the gel can be used without risk by pregnant women, small children or patients with damaged metabolisms.  There is no danger of further allergising by systemic ingredients, preservatives or other additives. There is also no danger of dependency. The patients sense of smell and taste are unaffected. The gel is cheap and easy to use.
Partcipants will undergo a 75g oral glucose tolerance test (OGTT) to document baseline insulin secretion kinetics. One week later, OGTT will be repeated after administering a single dose of ferrous sulphate (120 mg of elemental iron) 2 hours prior to the test.
The patients in this group:oral drug therapy from onset of the low pollen stage (August 1st, 2020) to the end of the pollen stage (September 30, 2020). Intranasal corticosteroids (mometasone furoate) from the high pollen stage (August 14, 2020) to the end of the pollen stage (September 30, 2020).
The present invention relates to an ultrasound-derived proxy for physical quantity. According to the present invention, in order to estimate ultrasound-based proxy using an ultrasound scanner (10), one or more ultrasound measurements are transformed (34) into biomarkers of different modalities. For example, a measurement of a standard biomarker is provided from histology or laboratory test assays. The transformation (34) allows selection (30) of one of various models for allowing the ultrasound measurements to be related to the biomarkers using a user-selected model. Also, an ultrasound scan sequence can be optimized (32) for the biomarkers and the user-selected model. In addition, as compared to standard biomarkers, the improvement in use of the ultrasound measurements more likely results in acceptance of less expensive and more easily obtained ultrasound measurements in diagnosis.
In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
OBJECTIVE: It has been suggested that choroid plexus calcifications (CPC) may be associated with glymphatic system dysfunction and with disturbed slow-wave (N3) sleep. If this is the case, volumetric analysis of CPC could be used to estimate the functional ability of the glymphatic system. However, data on this association is limited. This study aims to assess the association between percentages of N3 sleep - used as a putative marker of glymphatic system activity - and the volume of CPC in older adults.
PATIENTS AND METHODS: Community-dwelling individuals aged ≥60 years enrolled in the Atahualpa Project Cohort received head CTs (for automated determinations of CPC volume) and a single-night polysomnography (PSG) for quantification of N3 sleep percentages. Multivariate linear regression and non-parametric models were fitted to assess the association between these variables.
RESULTS: A total of 125 older adults (median age: 65 years; 32 % males) were included. The mean percentage of N3 sleep was 12.4±9.1 %, and the mean volume of CPC was 655±345.3 µL. Non-parametric locally weighted scatterplot smoothing showed that the volume of CPC increased as the percentage of N3 sleep increased, but only when N3 sleep is reduced (up to 12 % of total sleep time). The significance disappeared when PSG parameters were included in the model as well as in participants with normal N3 sleep percentages.
CONCLUSIONS: Study results suggest that in the presence of severe reductions in N3 sleep, increased CPC volume may be a manifestation of choroid plexus compensation or adaptation, and not necessarily dysfunction.
PD is commonly associated with depression, but conventional antidepressants have limited efficacy in patients with PD and may exacerbate motor symptoms. SAM-e is available in the United States as a food supplement and is promoted as a mood enhancer. SAM-e improves dopamine transmission, may have a beneficial effect on dopamine receptors, and may be a good alternative to the currently-used antidepressants in patients with PD. This study will investigate whether SAM-e is safe and effective in the treatment of depression associated with PD. The efficacy of SAM-e will be compared to placebo and to escitalopram, a selective serotonin reuptake inhibitor commonly used for the treatment of depression in PD.

Participants in this study will be randomly assigned to receive SAM-e, escitalopram, or placebo for 12 weeks. Some participants may choose to extend treatment for an additional 12 weeks (for a total of 24 weeks on study medication). Participants will have study visits at entry and Weeks 2, 4, 8, and 12. Study visits will include neurological evaluation, psychiatric evaluation, blood tests, and quality of life questionnaires. A telephone interview will be conducted at Week 10.
In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is \<70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
Silicosis is the most common type of pneumoconiosis, having a high incidence in workers chronically exposed to crystalline silica (CS). No specific medication exists for this condition. GHK, a tripeptide naturally occurring in human blood and urine, has antioxidant effects. We aimed to investigate the therapeutic effect of GHK-Cu on silicosis and its potential underlying molecular mechanism. An experimental silicosis mouse model was established to observe the effects of GHK-Cu on lung inflammation and fibrosis. Moreover, the effects of GHK-Cu on the alveolar macrophages (AM) were examined using the RAW264.7 cell line. Its molecular target, peroxiredoxin 6 (PRDX6), has been identified, and GHK-Cu can bind to PRDX6, thus attenuating lung inflammation and fibrosis in silicosis mice without significant systemic toxicity. These effects were partly related to the inhibition of the CS-induced oxidative stress in AM induced by GHK-Cu. Thus, our results suggest that GHK-Cu acts as a potential drug by attenuating alveolar macrophage oxidative stress. This, in turn, attenuates the progression of pulmonary inflammation and fibrosis, which provides a reference for the treatment of silicosis.
PURPOSE:To provide a safe agent for suppressing formation of lipid peroxide, having low side effect compared with conventional substance and excellent effect for suppressing the formation of lipid peroxide and useful as pharmaceuticals, quasi drugs and cosmetics. CONSTITUTION:The objective effective and safe agent for suppressing the formation of lipid peroxide can be produced by using a lactoferrin as an active component. The amount of the lactoferrin is >=0.001wt.% (preferably >=0.01wt.%) and the agent is coated, rubbed or sprayed (aerosol) to the skin in the form of solution, powder, sol, gel, emulsion, wax and various other forms. It can be used also as an additive for the conventional cosmetic or external agent by conventional process. Since the compound is stable to various other additives and cosmetic bases, it can be used in combination with the substances. Any lactoferrin including those produced by tissue culture or chemical synthesis can be used in the present process provided that the compound has an iron- bonding capability.
Novel glycosides, especially steroidal glycosides, and a novel method of their production, are provided. For the novel method of producing novel glycosides, hydroxysteryl compounds are glycosylated with tri-O-acyl glucal using molecular iodine as a reaction catalyst. In this method an alcohol or phenol, especially a hydroxy-steroid such as a water-insoluble cholesterol, is glycosylated, such that the glycosylation is performed in a single step. The resulting steryl pyranoside is by oxidation converted to the corresponding 7-ketosteryl di-O-acyl-pyranoside. The latter pyranoside is selectively reduced to provide the corresponding 7-(beta)-hydroxysteryl 2,3-dideoxy-(alpha)-D-erythro-hex-2-enopyranoside. The steroidal glycosides obtained in this way possess valuable pharmacological properties. In particular, the glycosides in vivo exhibit a selective cell-destructive activity on malignant cells which activity is substantially free of side effects on normal cells. The glycosides also possess a drive-enhancing (stimulating) activity and an anti-inflammatory (immunosuppressive or immunoregulatory) activity.
Considerable evidence suggests that musical education induces structural and functional neuroplasticity in the brain. This study aimed to explore the potential impact of such changes on word-reading proficiency. We investigated whether musical training promotes the development of uncharted orthographic regions in the right hemisphere leading to better reading abilities. A total of 60 healthy, right-handed culturally matched professional musicians and controls took part in this research. They were categorised as normo-typical readers based on their reading speed (syl/sec) and subdivided into two groups of relatively good and poor readers. High density EEG/ERPs were recorded while participants engaged in a note or letter detection task. Musicians were more fluent in word, non-word and text reading tests, and faster in detecting both notes and words. They also exhibited greater N170 and P300 responses, and target-non target differences for words than controls. Similarly, good readers showed larger N170 and P300 responses than poor readers. Increased reading skills were associated to a bilateral activation of the occipito/temporal cortex, during music and word reading. Source reconstruction also showed a reduced activation of the left fusiform gyrus, and of areas devoted to attentional/ocular shifting in poor vs. good readers, and in controls vs. musicians. Data suggest that music literacy acquired early in time can shape reading circuits by promoting the specialization of a right-sided reading area, whose activity was here associated with enhanced reading proficiency. In conclusion, music literacy induces measurable neuroplastic changes in the left and right OT cortex responsible for improved word reading ability.
Increased blood pressure. In the postpartum hemorrhage series, 5/115 (4%) of patients had an increase of blood pressure reported as a side effect. The degree of hypertension was moderate and it is not certain as to whether this was in fact due to a direct effect of carboprost tromethamine or a return to a status of pregnancy associated hypertension manifest by the correction of hypovolemic shock. In any event the cases reported did not require specific therapy for the elevated blood pressure. Use in patients with chorioamnionitis. During the clinical trials with carboprost tromethamine, chorioamnionitis was identified as a complication contributing to postpartum uterine atony and hemorrhage in 8/115 (7%) of cases, 3 of which failed to respond to carboprost tromethamine. This complication during labor may have an inhibitory effect on the uterine response to carboprost tromethamine similar to what has been reported for other oxytocic agents.1

1Duff, Sanders, and Gibbs; The course of labor in term patients with chorioamnionitis; Am. J. Obstet. Gynecol.; vol. 147, no. 4, October 15, 1983 pp 391–395.